Cardiovalve Transfemoral Mitral Valve System in Patients at High Surgical Risk With Severe Mitral Regurgitation

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The Cardiovalve system is a replacement valve delivered through a transfemoral access and transseptal approach and is intended for symptomatic patients with Mitral regurgitation for whom surgical options are not feasible.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years

• NYHA functional II, III or ambulatory IV

• Severe mitral regurgitation (MR grade 3-4+)

• High risk for conventional open mitral valve repair or replacement surgery in the consideration of the site Heart Team (including a cardiac surgeon, a cardiologist and imaging specialist as a minimum)

• Able to undergo Transesophageal Echocardiography (TEE).

• Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed.

• The subject commits to return for the scheduled post-operative follow-up visits at the hospital.

• Suitable for femoral access procedure and transseptal catheterization

• Native mitral valve geometry and size and LV outflow tract characteristics compatible with the Cardiovalve

Locations
Other Locations
Lithuania
Hospital of the Lithuanian University of Health Sciences ligoninė Kauno
RECRUITING
Kaunas
Contact Information
Primary
Nitza Shoham, PhD
nitza@cardiovalve.com
+972765388142
Backup
Ronit Pick
ronit@cardiovalve.com
Time Frame
Start Date: 2017-10-12
Estimated Completion Date: 2026-10-30
Participants
Target number of participants: 10
Treatments
Experimental: Cardiovalve treatment
Patients that implanted with the Cardiovalve device
Related Therapeutic Areas
Sponsors
Collaborators: Meditrial Europe Ltd.
Leads: Cardiovalve Ltd.

This content was sourced from clinicaltrials.gov